ArticleMolecular neurobiology2012
Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.
Article in Molecular neurobiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- TridentateFrontiers in neurology · 2022Article
- Oxygen Sensing and Signaling in Alzheimer's Disease: A Breathtaking Story!Cellular and molecular neurobiology · 2022Review
- Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis.Nature neuroscience · 2021Article
- Cell death pathways: intricate connections and disease implications.The EMBO journal · 2021Review
- Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.Handbook of experimental pharmacology · 2021Review
- Combination Drug Therapy for the Management of Alzheimer's Disease.International journal of molecular sciences · 2020Review
- Ferroptosis and Its Potential Role in Human Diseases.Frontiers in pharmacology · 2020Review
- Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease.Cellular and molecular neurobiology · 2019Review
- Genetic analysis of a novel antioxidant multi-target iron chelator, M30 protecting against chemotherapy-induced alopecia in mice.BMC cancer · 2019Article
- Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway.Journal of Alzheimer's disease : JAD · 2017Article
- Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone.Neurochemical research · 2015Article
- New approaches to treating Alzheimer's disease.Perspectives in medicinal chemistry · 2015Article
- Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.Frontiers in aging neuroscience · 2015Review
- From single target to multitarget/network therapeutics in Alzheimer's therapy.Pharmaceuticals (Basel, Switzerland) · 2014Article
- Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.Frontiers in aging neuroscience · 2014Article
- Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Current neuropharmacology · 2014Article
- Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.Experimental neurobiology · 2013Article
- High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease.Frontiers in aging neuroscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on a multimodal drug design strategy for age-related neurodegenerative diseases, we have synthesized a multifunctional nontoxic, brain-permeable iron-chelating compound, M30, possessing the neuroprotective N-propargyl moiety of the anti-Parkinsonian drug, monoamine oxidase-B inhibitor, rasagiline and the antioxidant-iron chelator moiety of the 8-hydroxyquinoline derivative of the iron chelator, VK28. In the present short overview, we describe the neuroprotective and the neurorestorative activity of M30, acting against multiple brain targets, including regulation on amyloid β, neurogenesis, and activation of hypoxia inducible factor signaling pathways. The diverse pharmacological properties and several pathological targets of M30 make this drug potential valuable for therapeutic strategy of Alzheimer's-like neuropathology and aging.
Indexed as
Identifiers
22847630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.